Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
Have a look!:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
IAG sp languishing @ 147.7p.
With other airlines having recently reported good figures, holiday Co's too!!
It really is astonishing to me.
I bought for £1.65p plus, hope the traders wake up!
At lest the sp is up a bit so far today..... 2.78%.
All IMHO.
Indeed. Why do you too? Is it you I wonder?
Last December when the sp was sub 10p! My typing is not that bad, is it?
To have bought @ sum 10p a share before xmass! I'm hoping they will buy soon!
Up 2.67%. Breakout?
Stargate.
You posted:-"Sp, shortly before close has retreated back to yesterday close of 18.5, so a two day close, means 18.5 is resistance. Only buy either if close above 18.5, or if confident of price near closing time. DYOR.". That was a few days ago I think. At todays close the Mid price is 18.75p (18.5p bid, 19p ask).
The sp has met your criteria to BUY it seems.
Are you in, or going to get in??
The presentation:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO.
Hope so!
Up 1.35%. Every little helps!
Have a look!:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
Seemed ok to me. A little miffed???
Being simply EZY had good results and so did WIZZ and Jet2. Also TUI said demand was good, yet their sp has dived strangely?? In fact might buy some TUI...
Moment and they have conformed in an RNS:-"Cash runway extended into Q2 2025 ".
Obviously they need to build sales and it seems they now have the means to do that. For example:-
The RNS's of 2nd Jan (the top 100 Japanese Plc Eisai contract) about the HER2 assay test . As I understand it using Angle's Parsortix machine to catch circulating cancer cells and test them with this assay is THE ONLY WAY of monitoring the HER2 status of breast cancer after the initial biopsy. This opens the door to doing deals with "household names" who also need a way of monitoring this extremely important HER2 (human epidermal growth factor receptor 2). The companies need to be able to test this to find out if the status has changed during the treatments they are testing. They suspect that if the HER2 status changes during treatment their treatment's effect will radically change. Until now there was IMHO NO WAY of proving this theory. If the theory is proved correct eventually we may find Angles parsortix machine being used to see if a treatment will work............ Massive potential!
All IMHO.
You know. This sp that was under 10p last December, that is now ***19p***. LOL! LOL! LOL!
The sp has doubled in 2 months so the trend is set??
Davey50.
"being rude"!! Why do you say that? I did not intend to be rude.
If what you suspect is happening I suspect they are choosing Angle Plc precisely because the sp has nearly doubled in 2 months. Thus the odds of their winning the short big bet would seem to be slightly in their favour, even of they "step on a land mine" in the short tearm. All a bit odd!
And now the MM's are showing us trades from some earlier time to confuse everyone (could be an earlier day of course) !! LOL!! I see there are 2nr. 50K trades there @ 19.925p which is interesting.
Have a look!:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO.
Davey50.
I don't think your theory computes.
Apart from anything else when the sp bid increases as they do their in and out big trades (what you suspect) it would trigger any sell limits instantly so they could run into a huge one, could they not?
The bottom line is the sp was 10p before xmass. The mid price as I type this is 19p.
The RNS's of 2nd Jan (finally dawning on the market thesignificance of the top 100 Japanese Plc Eisai contract) and the "Game changer" RNS of 4th Jan (Molecule analysys).
Have a look!:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
All IMHO.
Who cares?
Up 5.41%.
Have a look!:-
https://www.youtube.com/watch?v=cnQ6M05BiBY
Up 4%.
Zidane.
So when can Directors buy shares?
"When in possession of price-sensitive information" it says on the www.
You say "when they are aware of ongoing discussions over large contracts.".
Where do you draw the line?
Mr Newland said it took "the best part of a year" to negotiate the Eisai Inc. contract! That was to do with just a HER2 assay test announced 2nd January.
The "Gamechanger" Molecular analysis results Angle Plc announced on 4th Jan means they have contacted the following Co's as Mr Nowland said in the presentation. Reason? The use of parsortix to analyse circulating tumour cells could lead to increased sales of these cancer drugs:-
-- PIK3CA (E545K): Alpelisib (Piqray(R) ) marketed by Novartis
-- EGFR (T790M): Tagrisso (Osimertinib(R) ) marketed by Astra Zeneca
-- ESR1 (K303R): Elacestrant (Oserdu(R) ) marketed by Menarini
-- MTOR (T1977K): Everolimus (Afinitor(R) ) marketed by Novartis
So when can the Directors buy???
I think this is a massive grey area.
All IMHO.